Intermediate-dose HAD Regimen for CEBPA Double-mutated AML — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Intermediate-dose HAD Regimen for CEBPA Double-mutated AML — Stella

Recruiting

Back to AML trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Blood Hospital, Tianjin, Tianjin Municipality

Key details

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment target

~148 participants

Started

August 2024

Primary completion

August 2026

Age range

14 Years – 54 Years

Last updated January 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov